Jiangxi Fushine Pharmaceutical Co.Ltd(300497) independent director
Independent opinions on matters related to the 27th meeting of the third board of directors of the company are in accordance with the company law of the people’s Republic of China (hereinafter referred to as the “company law”), the securities law of the people’s Republic of China (hereinafter referred to as the “Securities Law”) and the guiding opinions on the establishment of independent director system in listed companies As an independent director of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) (hereinafter referred to as “the company”), we are based on the principle of prudence and independent judgment, The independent opinions on the matters considered at the 27th meeting of the third board of directors are as follows:
1、 Independent opinions on changing the purpose of raising funds by issuing shares to specific objects and adding new raised investment projects
After verification, the independent directors believe that the necessary approval procedures have been fulfilled for the purpose of issuing shares to specific objects and the new raised investment projects; Comply with the requirements of relevant laws, regulations and regulatory documents such as the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the guidelines for the standardized operation of GEM listed companies of Shenzhen Stock Exchange, etc. The change of the purpose of some raised funds is in line with the actual situation of the company, conducive to the long-term development of the company and improve the use efficiency of raised funds, in line with the interests of all shareholders, and there is no damage to the interests of shareholders.
Therefore, we unanimously agreed on the matter and submitted relevant proposals to the general meeting of shareholders of the company for deliberation.
2、 Independent opinions on the appointment of deputy general manager of the company
After verification, the independent directors believe that Mr. Wei Haipeng has the qualification and ability to serve as senior managers of the company, and there is no situation that he is not allowed to serve as specified in the company law and the articles of association, and there is no situation that he is prohibited from entering the market determined by the CSRC and the prohibition has not been removed, and there has been no case that he has been banned by the CSRC There are no other circumstances in which a stock exchange may not serve as a senior manager of a listed company. Their qualifications are legal, and their nomination and appointment procedures comply with relevant regulations.
We therefore agreed on the matter.
(there is no text on this page, which is the signature page of Jiangxi Fushine Pharmaceutical Co.Ltd(300497) independent directors’ independent opinions on matters related to the 27th meeting of the third board of directors of the company)
Signature of independent director:
Zhang Rui, Li Yan, Liu Hong
specific date
